Phase 1 study of cisplatin + sulfasalazine in patients with advanced gastric cancer. - CDDP+SASP

ational Cancer Center Hospital East0 个研究点目标入组 18 人开始时间: 2014年11月4日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Chemotherapy, radiation therapy or other investigational drugs within 2 weeks prior to enrollment. 2)Active bleeding. 3)Patient with any of the following symptoms within 6 months prior to administration of the drug;myocardial infarction, severe or unstable angina, congested heart failure,cerebrovascular accident containing transient ischemic attack or pulmonary embolism. 4)Uncontrolled bronchial asthma. 5)Patient with brain metastases. 6)Laparotomy or thoracotomy within 4 weeks to enrollment. 7)Known hypersensitivity to sulfa drugs or acetylsalicylic acid formulation. 8)Known history of serious adverse events due to cisplatin 9)Women during pregnancy or lactation, women suspected of being pregnant, women desiring future fertility. 10)Patient is judged by the investigator to be inappropriate for study participation for any reason. 11)Patient with Ulcerative colitis, or treated patient with sulfapyridine or 5-ASA derivative.

发起方

ational Cancer Center Hospital East